The future is regenerative medicine and BioStem Technologies (OTC: BSEM) is a growing company that is leading the way with innovation, exploding revenues, and breakthrough achievements.

This growing medtech company is harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies in advanced wound care. BSEM is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method.

Over the last few months, BSEM has achieved a series of clinical, regulatory, and financial milestones. This includes breakthrough results from a diabetic foot ulcer would closure study, strong Q1 financial results, approval to advance a new clinical trial in treating venous leg ulcers, and a notice of allowance from the U.S. Patent and Trademark Office for two U.S. patent applications.

BSEM has recently announced record preliminary net revenue of $72.5 million for Q1 2025. This is a 73% increase compared to $41.9 million in Q1 2024.The company also ended the quarter with cash on hand at $26.7 million, an increase from $22.8 million on December 31st, 2024. This was the strongest first quarter in the company’s history!

Over the past year Zacks Small Cap Research has been very bullish on BSEM and has been lifting its price target several times. After the company’s last financial report, the firm gave BSEM a price target of $35.50. Could Zacks be ready to lift their price target once again? It should be also noted that BSEM is in the process of uplisting its stock to the NASDAQ stock exchange, which should improve access and liquidity for investors!

Discover why BSEM is a company to put high on your radar, especially if Zacks lifts its price target again.

This is a paid advertisement. Headline Wealth is receiving compensation from A New Day Media, LLC. for sending this email. Headline Wealth does not advise its clients or any other person whether or not to buy or sell or take positions in securities. We are not registered as a broker, broker-dealer, investment adviser, agent or representative of the U.S. Securities and Exchange Commission, or any similar authority. We do not teach or recommend to any client their financial suitability to trade equities. All trading involves high risk and you can lose a substantial amount of money. The content provided in this email is a source of information only. The report has been prepared by a third party and Headline Wealth is in no way responsible for its content. This information is not a recommendation to buy, sell or hold any securities or other investments. All statements and expressions are the opinion of the author only and should not be construed as investment advice. This information has been prepared without taking into account your investment objectives or financial situation and is presented for illustrative and educational purposes only.